Medlumics lands a 14M€ new financing round

14.03.2024 - andera Life Sciences - Nos communiqués

Tubulis, au portefeuille d’Andera Partners, annonce la finalisation de sa levée de série B2 d’…

14.03.2024 - andera Life Sciences - Nos communiqués

Amolyt Pharma, au portefeuille d’Andera Partners, annonce son acquisition par AstraZeneca

21.02.2024 - andera Life Sciences - Nos communiqués

MMI Raises $110 Million in Series C Financing

12.02.2024 - andera Life Sciences - Recrutement

Internship Offer – Andera Life Sciences

14.11.2023 - andera Life Sciences - Nos communiqués

Andera Partners co-mène le financement de série C sursouscrit de 67,5 millions d’euros (72 mil…

27.10.2023 - andera Life Sciences - Nos communiqués

JenaValve Announces Late-Breaking Data from the ALIGN-AR Pivotal Trial Meeting Safety and Efficacy E…

11.10.2023 - andera Life Sciences - Nos communiqués

Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline

05.10.2023 - andera Life Sciences - Nos communiqués

Agomab Receives FDA Fast Track Designation for AGMB-129 in Fibrostenosing Crohn’s Disease and Starts…

24.07.2023 - andera Life Sciences - Nos communiqués

Crescendo Biologics secures $32M and announces expansion of CB307 Phase 1b trial in PSMA+ solid tumo…

27.06.2023 - andera Life Sciences - Nos communiqués

Allecra Therapeutics Submits New Drug Application to the U.S. FDA for EXBLIFEP® for the Treatment of…

01.06.2023 - andera Life Sciences - Nos communiqués

Inotrem announces publication of two key articles on nangibotide Phase II programs in peer-reviewed…

15.05.2023 - andera Life Sciences - Nos communiqués

Andera Partners co-dirige une série A de 40 millions d’euros pour Dualyx, une biotech belge qu…

20.04.2023 - andera Life Sciences - Nos communiqués

Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation A…

18.04.2023 - andera Life Sciences - Nos communiqués

Andera Partners soutient Ariceum Therapeutics dans l’extension de son financement de série A à…

13.04.2023 - andera Life Sciences - Nos communiqués

BioVentrix® clôture un tour de financement de série A de 48,5 millions de dollars